CoChat
Sign Up
Cited by 30Pancreatic and Hepatic Oncology ResearchGlobal Cancer Incidence and ScreeningPancreatitis Pathology and Treatment

A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas

Le, Hoa, Ziogas, Argyrios, Rhee, Jessica M., Lee, John G., Lipkin, Steven M., Zell, Jason A.·2008·Cancer Epidemiology, Biomarkers & Prevention
DOI 10.1158/1055-9965.epi-08-0417
Open this paper in CoChat — free account

Abstract

Background: Intraductal papillary mucinous neoplasms (IPMN) are distinct precursor lesions that can progress to pancreatic adenocarcinoma; thus, it has been of particular interest to cancer prevention researchers. We set out to do a population-based analysis of malignant IPMNs compared with other pancreatic subtypes to better delineate its characteristics and explore implications for prevention and management. Methods: We conducted a case-only analysis of California Cancer Registry data (2000-2007), including descriptive analysis of relevant clinical variables. Overall survival univariate analyses were conducted using the Kaplan-Meier method. Multivariate survival analyses were done using Cox proportional hazards ratios. Results: Overall, 15,296 pancreatic cancer cases were identified, including incident cases of 10,186 adenocarcinomas, 880 mucinous tumors, 568 endocrine tumors, 3,619 carcinoma not otherwise specified tumors, and 43 malignant IPMNs. Thirty-three (80.5%) IPMN cases had localized disease at presentation, eight had regional disease (19.5%), and no IPMNs were identified with distant disease (two were unstaged). Five-year overall survival was better for malignant IPMN cases (65%) compared with pancreatic endocrine tumors (30%), mucinous tumors (5%), carcinoma not otherwise specified (2%), and adenocarcinoma cases (2%). Compared with adenocarcinoma cases, malignant IPMN cases (hazard ratio = 0.19; 95% CI, 0.10-0.35), endocrine tumors (hazard ratio = 0.28; 95% CI, 0.25-0.32), and mucinous tumors (hazard ratio = 0.84; 95% CI, 0.77-0.90) had higher overall survival in a multivariate survival analysis after adjustment for age, gender, stage, race, socioeconomic status, surgery, chemotherapy, and radiation therapy. Conclusions: Pancreatic malignant IPMNs represent an uncommon pancreatic tumor subtype, uniquely characterized by early stage at presentation and better survival. (Cancer Epidemiol Biomarkers Prev 2008;17(10):2737–41)

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-08-0417

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Approximately 8% of all pancreatic ductal adenocarcinomas are believed to arise from premalignant mucinous cystic lesions of the pancreas.

    “Approximately 8% of all pancreatic ductal adenocarcinomas are believed to arise from premalignant mucinous cystic lesions of the pancreas.59”

    From Early detection of pancreatic cancer (2020) · cites this paper as [59]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Le, H., Ziogas, A., Rhee, J. M., Lee, J. G., Lipkin, S. M., & Zell, J. A.
Affiliations
  • UC Irvine Chao Family Comprehensive Cancer Center (US)
  • University of California, Irvine (US)
  • 2H.H. Chao Comprehensive Digestive Disease Center, Division of Gastroenterology, Department of Medicine;
ORCID
Venue
Cancer Epidemiology, Biomarkers & Prevention
Publisher
American Association for Cancer Research (AACR)
Published
2008-10-01
Volume
17
Issue
10
Pages
2737-2741
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
DOI
10.1158/1055-9965.epi-08-0417
OpenAlex
W2091243972
Cited by
30
References
19
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 3 · 2014: 1 · 2012: 1
FWCI
0.53
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Epidemiology Biomarkers & Prevention (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of California, Irvine
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
intraductal papillary mucinous neoplasm, pancreatic cancer, pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, mucinous pancreatic tumor, overall survival, tumor stage at presentation, pancreatic precursor lesions, cancer prevention
MeSH terms
Aged, Aged, 80 and over, Analysis of Variance, California, Adenocarcinoma, Mucinous, Cause of Death, Female, Humans, Male, Middle Aged, Retrospective Studies, Chi-Square Distribution, Proportional Hazards Models, Survival Analysis, SEER Program, Carcinoma, Pancreatic Ductal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review